Immuno Oncology | Topics

 
Thomas Marron, MD, PhD, on the Safety, Feasibility, and Immunogenicity of Neoantigen Peptide Vaccine PGV-001
April 11, 2021

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.

Leading Anticancer Immunotherapeutics to Be Assessed for Continued Use for Indications Granted Accelerate Approval
March 12, 2021

Indications for pembrolizumab, nivolumab, and atezolizumab are set for examination under the FDA’s Oncologic Drugs Advisory Committee for indications granted accelerated approval in breast, urothelial, gastric, and liver cancers.

FDA Lifts Clinical Hold on Phase 1/2 Trial Evaluating BPX-601 for Metastatic Pancreatic, Prostate Cancer
January 30, 2021

Bellicum Pharmaceuticals, the developer of BPX-601, can now begin enrolling patients to their phase 1/2 trial again without modification to the study protocol.